Skip to content

Pilot clinical study of Digestive Enzyme.

An Open Label, Pilot Clinical Study on Finding the Effect of a Food Supplement (Enzoveda#001) on Indigestion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018214
Enrollment
10
Registered
2019-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system

Interventions

Sponsors

Advanced Vital Enzymes Private limited
Lead Sponsor
Milagro Clinical Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: The Inclusion criteria are as follows (â??Yesâ?? to all the following will allow the subjects to be included into study) 1. Age: Adult-Above 18 years to 60 years, both male and female 2. Willing to sign written inform consent 3. Patients diagnosed one of the following signs and symptoms of indigestion Abdominal discomfort Flatulence Burping or belching Acidity and pain Heaviness in upper abdomen.

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows (â??Yesâ?? to any one of the following will allow PI to exclude the subject from enrolling into the study 1. Patients below 18 years and above 60 yrs. 2. Not willing to sign written inform consent 3. Allergic reactions to enzymes of similar composition. 4. Gastrointestinal disease or other condition resulting in inability to take oral medications 5. Uncontrolled heart disease or other serious chronic disease 6. Radiotherapy within 4 weeks prior to randomization 7. Patients suffering from chronic major illness, like- Hypertnesion, Jaundice, AIDS, Cancer, Tuberculosis, Diabetes Mellitus, Hepatitis B or C positive etc 8. Use of investigational agents within 4 weeks of randomization 9. Concurrent systemic corticosteroid therapy within 4 weeks of randomization. 10. Seriously ill and moribund patients with complications. 11. Patients unable to comply with the treatment regimen. 12. Pregnant women, lactating women and women of child bearing potential not following adequate contraceptive measure, women who were found positive for urine pregnancy test

Design outcomes

Primary

MeasureTime frame
To assess efficacy of Enzoveda#001 as a food supplement in patients suffering from indigestion and mean change in Visual Analogue Scale (VAS) from baseline to end of treatment.Timepoint: 7 days

Secondary

MeasureTime frame
Symptomatic relief from the symptoms of IndigestionTimepoint: 7 days

Countries

India

Contacts

Public ContactVikrant Kannojiya

Milagro clinical research

anjali@milagroclinicalresearch.com7400407196

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026